KCT0008731已完成Unknown
An 8-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Theracurmin ingestion on oxidative stress during exercise.
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30(Year) 至 59(Year)（—）
- 性别
- All
入选标准
- •1) Healthy adult males and females between the ages of 30 and 59 years.
- •2) The people who agree to participate in this human clinical trial and complete a written informed consent form before the start of the human clinical trial.
排除标准
- •1) Have or are currently being treated for a serious cardiovascular, immune, respiratory, gastrointestinal/liver and biliary, renal and urinary, neurologic, musculoskeletal, psychiatric, or infectious disease
- •2) Diagnosed with thyroid disease diabetes and currently taking related medications
- •3) Have had a surgical procedure within 6 months of Visit 1
- •4) Unable to perform treadmill exercise
- •5) Maximal oxygen uptake (VO2 max) in the exercise is greater than or equal to grade 1 for their age group
- •6) Continued regular exercise within 3 months prior to Visit 1 (3 or more days per week, 30 minutes or more of exertion per day).
- •7) BMI less than or equal to 18 kg/m2 and greater than or equal to 30 kg/m2
- •8) Those who score 47.7 or more in the balance category and 67.3 or more in the variety category on the Nutrition Index Questionnaire.
- •9) Excessive alcohol consumers (420 g/week or more: about 7 bottles/week, 1 bottle/day based on soju) or alcoholics
- •10) Smokers, Drug addicts (However, those who have quit smoking for more than 1 year as of Visit 1 are eligible to participate.
- •11) Subjects who have taken nutritional supplements (vitamins, amino acids, creatine, protein drinks, etc.) within 2 months prior to Visit 1.
- •12) Use of dietary supplements (red ginseng, chlorella, green tea extract, spirulina, propolis extract, coenzyme Q10, squalene, tomato extract, etc.) or medications (lipid-lowering, anti-inflammatory, blood pressure-lowering, antibiotics, aspirin, anti-inflammatory, blood glucose-lowering, anticoagulants, steroids, etc.) and chinese medicine
- •13) Subjects with uncontrolled hypertension (systolic blood pressure greater than or equal to 140 mmHg or diastolic blood pressure greater than or equal to 100 mmHg, measured after 10 minutes of subject rest)
- •14) Subjects who have lost more than 4 kg of body weight within 1 month of Visit 1
- •15) Pregnant or lactating women or those planning to become pregnant during the course of this human study
- •16) Participation in another interventional clinical trial (including human clinical trials) within 3 months of Visit 1, or plans to participate in another interventional clinical trial (including human clinical trials) after the start of this human clinical trial.
- •17) Subjects who are sensitive or allergic to any of the food ingredients in this human clinical trial.
- •18) Subjects deemed unsuitable by the investigator for any other reason.
研究者
相似试验
招募中
不适用
An 8-week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of probiotics NVP-1704 on sleep improvementMental and behavioural disordersKCT0009096Seoul National University Bundang Hospital120
招募中
不适用
A 8-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Saccaharum Officinalis wax alcohols(Policosanol) on improvement of blood cholesterolKCT0006606Wonkwang University. Iksan Korean Medicine Hospital80
尚未招募
不适用
Clinical trial to evaluate the efficacy and safety of GyejigaChulbu-tang on degenerative osteoarthritisDiseases of the musculo-skeletal system and connective tissueKCT0003124Wonkwang University, Gwangju Medical Center56
已完成
不适用
Human trial study to evaluate the efficacy and safety of ISD on immune functioKCT0004387Medience80
已完成
不适用
A 8-week, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Beta-Glucan derived from Split gill Mushroom, Schizophyllum commune Fr. for improving intestinal healthKCT0006657Quegen Biotech80